Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -585.20% is 93% above its 5-year average of -8073.46%, near the high end of its 5-year range (-115329.27%–0.00%).
78.20% above its 12-month average of -2684.35%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): -2141.61%.
OPERATING MARGIN
-585.20%
OPERATING MARGIN AVG TTM
-2684.35%
OPERATING MARGIN AVG 3Y
-8575.17%
OPERATING MARGIN AVG 5Y
-8073.46%
OPERATING MARGIN AVG 10Y
-3479.42%
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+78.20%
CURRENT VS 3Y AVG
+93.18%
CURRENT VS 5Y AVG
+92.75%
CURRENT VS 10Y AVG
+83.18%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Ovid Therapeutics Inc.
Market Cap
$442.34M
Operating Margin
-585.20%
TTM Avg
-2684.35%
3Y Avg
-8575.17%
5Y Avg
-8073.46%
Market Cap
$439.55M
Operating Margin
-11.75%
TTM Avg
-88.01%
3Y Avg
-269.63%
5Y Avg
-547.01%
Market Cap
$445.71M
Operating Margin
0.00%
TTM Avg
-95.56%
3Y Avg
-362.67%
5Y Avg
-2402.18%
Market Cap
$438.07M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$435.61M
Operating Margin
-883.31%
TTM Avg
-584.88%
3Y Avg
-293.14%
5Y Avg
-195.43%
Market Cap
$431.97M
Operating Margin
-15.26%
TTM Avg
-21.73%
3Y Avg
-43.66%
5Y Avg
-43.15%
Market Cap
$426.51M
Operating Margin
-212.92%
TTM Avg
-108.19%
3Y Avg
-56995.46%
5Y Avg
-38056.30%
Market Cap
$424.10M
Operating Margin
-8.63%
TTM Avg
-11.52%
3Y Avg
-18.04%
5Y Avg
-16.64%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | $442.34M | -585.20% | -2684.35% | -8575.17% | -8073.46% |
| Assembly Biosciences, Inc. (ASMB)vs › | $439.55M | -11.75% | -88.01% | -269.63% | -547.01% |
| Capricor Therapeutics, Inc. (CAPR)vs › | $445.71M | 0.00% | -95.56% | -362.67% | -2402.18% |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $438.07M | 0.00% | 0.00% | 0.00% | 0.00% |
| YD Bio Limited Ordinary Shares (YDES)vs › | $435.61M | -883.31% | -584.88% | -293.14% | -195.43% |
| NRC Health (NRC)vs › | $452.54M | 10.53% | 20.52% | 24.67% | 27.45% |
| NeuroPace, Inc. (NPCE)vs › | $431.97M | -15.26% | -21.73% | -43.66% | -43.15% |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $426.51M | -212.92% | -108.19% | -56995.46% | -38056.30% |
| NeoGenomics, Inc. (NEO)vs › | $424.10M | -8.63% | -11.52% | -18.04% | -16.64% |
| Tectonic Therapeutic, Inc. (TECX)vs › | $422.86M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
100.0%
Operating Margin
-585.2%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | -2141.61% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | -1712.12% |
| 2025-09-30 | -9487.12% |
| 2025-06-30 | -80.88% |
| 2025-03-31 | -9653.85% |
| 2024-12-31 | -14107.89% |
| 2024-09-30 | -7645.09% |
| 2024-06-30 | -12140.24% |
| 2024-03-31 | -11768.24% |
| 2023-12-31 | -12808.45% |
| 2023-09-30 | -11035.78% |
| 2023-06-30 | -18896.00% |
| 2023-03-31 | -22563.64% |
| 2022-12-31 | -26302.75% |
| 2022-09-30 | -115329.27% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | -1125.47% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 84.73% |
| 2020-12-31 | -378.58% |
| 2020-09-30 | -237.25% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
